Andrew Stamford
Overview
Explore the profile of Andrew Stamford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ginn J, Jiang X, Sun S, Michino M, Huggins D, Mbambo Z, et al.
ACS Infect Dis
. 2021 Feb;
7(2):435-444.
PMID: 33527832
Tuberculosis remains a leading cause of death from a single bacterial infection worldwide. Efforts to develop new treatment options call for expansion into an unexplored target space to expand the...
2.
Lama L, Adura C, Xie W, Tomita D, Kamei T, Kuryavyi V, et al.
Nat Commun
. 2019 May;
10(1):2261.
PMID: 31113940
Cyclic GMP-AMP synthase (cGAS) is the primary sensor for aberrant intracellular dsDNA producing the cyclic dinucleotide cGAMP, a second messenger initiating cytokine production in subsets of myeloid lineage cell types....
3.
Zhu C, Wang L, Zhu Y, Guo Z, Liu P, Hu Z, et al.
Bioorg Med Chem Lett
. 2017 Feb;
27(5):1124-1128.
PMID: 28185720
The paper describes the SAR/SPR studies that led to the discovery of phenoxy cyclopropyl phenyl acetamide derivatives as potent and selective GPR119 agonists. Based on a cis cyclopropane scaffold discovered...
4.
Wu W, Hao J, Domalski M, Burnett D, Pissarnitski D, Zhao Z, et al.
ACS Med Chem Lett
. 2016 May;
7(5):498-501.
PMID: 27190600
In our efforts to develop second generation DPP-4 inhibitors, we endeavored to identify distinct structures with long-acting (once weekly) potential. Taking advantage of X-ray cocrystal structures of sitagliptin and other...
5.
Girijavallabhan V, Arasappan A, Bennett F, Chen K, Dang Q, Huang Y, et al.
Nucleosides Nucleotides Nucleic Acids
. 2016 Apr;
35(6):277-94.
PMID: 27104963
Novel 2'-modified guanosine nucleosides were synthesized from inexpensive starting materials in 7-10 steps via hydroazidation or hydrocyanation reactions of the corresponding 2'-olefin. The antiviral effectiveness of the guanosine nucleosides was...
6.
Zhou G, Aslanian R, Gallo G, Khan T, Kuang R, Purakkattle B, et al.
Bioorg Med Chem Lett
. 2016 Jan;
26(4):1348-54.
PMID: 26781932
Novel bicyclic adenosine A(2A) antagonists with an aminoquinazoline moiety were designed and synthesized. The optimization of the initial lead compound based on in vitro and in vivo activity has led...
7.
Dai X, Stamford A, Liu H, Neustadt B, Hao J, Kowalski T, et al.
Bioorg Med Chem Lett
. 2015 Oct;
25(22):5291-4.
PMID: 26433449
The design and synthesis of two conformationally restricted oxazabicyclo octane derivatives as GRP119 agonists is described. Derivatives of scaffold C, with syn configuration, have the best overall profiles with respect...
8.
Liu P, Hu Z, DuBois B, Moyes C, Hunter D, Zhu C, et al.
ACS Med Chem Lett
. 2015 Aug;
6(8):936-41.
PMID: 26288697
We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for...
9.
Deng Q, Lim Y, Anand R, Yu Y, Kim J, Zhou W, et al.
Bioorg Med Chem Lett
. 2015 Jun;
25(15):2958-62.
PMID: 26048804
Molecular modeling was performed on a triazolo quinazoline lead compound to help develop a series of adenosine A2A receptor antagonists with improved hERG profile. Superposition of the lead compound onto...
10.
Caldwell J, Mazzola R, Durkin J, Chen J, Chen X, Favreau L, et al.
Bioorg Med Chem Lett
. 2014 Dec;
24(23):5455-9.
PMID: 25455483
The synthesis of a series of iminoheterocycles and their structure-activity relationships (SAR) as inhibitors of the aspartyl protease BACE1 will be detailed. An effort to access the S3 subsite directly...